Treatment of pediatric chronic pain with tramadol hydrochloride: siblings with Ehlers-Danlos syndrome - Hypermobility type.

Abstract

OBJECTIVE:

To evaluate the effectiveness of tramadol hydrochloride for the treatment of chronic pain refractory to previous treatment in two pediatric patients.

METHODS:

Tramadol hydrochloride was administered (50 mg/day to 150 mg/day) to two siblings with Ehlers-Danlos syndrome - Hypermobility type refractory to previous pharmacological treatments, and changes in pain intensity and physical activity were assessed.

RESULTS:

Pain intensity decreased and physical activity improved within days of starting therapy. Positive results have been maintained for 30 months.

CONCLUSIONS:

Tramadol hydrochloride was a safe and effective treatment for relieving chronic pain in two pediatric patients suffering from the hypermobility type of Ehlers-Danlos syndrome. No morbidity or side effects were noted during the 30-month follow-up.

• Authors: Stephen C Brown, Jennifer Stinson
• Journal: Pain research & management (Pain Res Manag) Vol. 9 Issue 4 Pg. 209-11 ( 2004) ISSN: 1203-6765 [Print] United States
• PMID: 15605135 (Publication Type: Case Reports, Journal Article)

Chemical References

• Analgesics, Opioid
• Tramadol

Topics

• Analgesics, Opioid (administration & dosage)
• Child
• Child, Preschool
• Chronic Disease
• Ehlers-Danlos Syndrome (complications)
• Humans
• Joint Instability (etiology)
• Male
• Pain (drug therapy, etiology)
• Tramadol (administration & dosage)